At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 417 enrolled
Drug / intervention
botulinum toxin Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BOTOX® in the Treatment of Crow's Feet Lines in China
In Brief
A Phase 3 clinical trial evaluating botulinum toxin Type A and Normal Saline for Lateral Canthal Lines and Crow's Feet Lines. Completed, enrolled 417 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, Crow's Feet Lines
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartSep 2014
Primary CompletionFeb 2015
Study CompletionJun 2015
TodayJul 2026
First PostedJul 21, 2014
Enrollment StartSep 1, 2014
Primary CompletionFeb 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.9 years ago
Interventions
botulinum toxin Type Abiological
botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
Normal Salinedrug
Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.